Recent performance snapshot

BioCryst Pharmaceuticals (BCRX) stock has been relatively weak recently, with the price down 0.7% on the day, 1.9% over the past week, and 2.4% over the past month.

Over the past 3 months the stock has fallen 3.9%, and it is down 24.3% over the past year, despite being up 12.1% year to date. This pattern may catch the attention of investors tracking biotech volatility.

At a share price of $8.41, BioCryst Pharmaceuticals shows fading short term share price momentum, while the 1 year total shareholder return is down 24.3%, despite a slightly positive 3 year total shareholder return.

If BioCryst has you looking beyond a single biotech, this could be a good moment to scan other opportunities through our screener focused on 38 healthcare AI stocks

With BioCryst trading at $8.41 against an analyst price target of $21.30 and an indicated intrinsic discount of 88%, is this a genuine mispricing, or is the market already factoring in future growth correctly?

Most Popular Narrative: 60.5% Undervalued

With BioCryst Pharmaceuticals last closing at $8.41 against a narrative fair value of $21.30, the widely followed view is building in a sizeable upside gap that hinges on how the rare disease portfolio plays out.

Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.

Want to see what is baked into that view? Revenue, margins, and earnings are all reset in this narrative, along with a premium future earnings multiple. Curious which assumptions really carry the fair value to $21.30? The full story joins those moving parts into one valuation arc.

Result: Fair Value of $21.30 (UNDERVALUED)

However, this hinges on ORLADEYO remaining resilient against rising HAE competition and on early stage pipeline bets paying off without stretching costs too far.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If the mixed signals on BioCryst leave you torn between caution and optimism, use this window to review the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not stop with a single biotech when there are other focused stock ideas you can review in minutes using the Simply Wall Street Screener.

• Spot potential value by scanning 48 high quality undervalued stocks that pair solid fundamentals with pricing that may not fully reflect their profiles.
• Prioritize resilience by checking 63 resilient stocks with low risk scores featuring companies with lower overall risk scores that may suit a steadier approach.
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.